Finnmed Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-12-2024
- Paid Up Capital ₹ 0.10 M
as on 15-12-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 25.84%
(FY 2020)
- Profit 86.44%
(FY 2020)
- Ebitda 56.44%
(FY 2020)
- Net Worth 165.11%
(FY 2020)
- Total Assets 14.48%
(FY 2020)
About Finnmed Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vilas Kute, Ramesh Kedar, Pratap Somwanshi, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74999PN2017PTC171292
- Company No.
171292
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Finnmed Biotech?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vilas Kute  | Director | 05-Jul-2017 | Current |
| Ramesh Kedar | Director | 05-Jul-2017 | Current |
| Pratap Somwanshi | Director | 05-Jul-2017 | Current |
| Jayshree Kale | Director | 05-Jul-2017 | Current |
| Rajesh Patil | Director | 05-Jul-2017 | Current |
Financial Performance of Finnmed Biotech.
Finnmed Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 25.84% increase. The company also saw a substantial improvement in profitability, with a 86.44% increase in profit. The company's net worth Soared by an impressive increase of 165.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Finnmed Biotech?
In 2018, Finnmed Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shivkailas Developers And Builders Company Private LimitedActive 20 years 14 daysVilas Kute is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Finnmed Biotech?
Finnmed Biotech has a workforce of 6 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Finnmed Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Finnmed Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
